Jobs
-
Insmed has announced that in a Phase 2 clinical trial of Arikayce (formerly Arikace) inhaled liposomal amikacin for nontuberculous mycobacterial (NTM) lung infections, the product failed to produce a statistically significant reduction in mycobacterial density;… Read more . . .
-
Vectura has announced that under a license agreement with “the US division of a leading international pharmaceutical company” signed in 2011, it has reached a milestone associated with the US development of its VR315 salmeterol/fluticasone… Read more . . .
-
3M Drug Delivery Systems has announced that Cindy R. Kent has succeeded James Ingebrand as President and General Manager, effective February 2014. Ingebrand will now head 3M’s dental division. Kent joined 3M in October 2013… Read more . . .
-
According to a report in the Wall Street Journal, a court in Cologne, Germany has issued a preliminary injunction preventing Sandoz from marketing its AirFluSal Forspiro in Germany. GlaxoSmithKline had argued that Sandoz’s salmeterol/fluticasone DPI… Read more . . .
-
According to Mylan, the United States District Court for the Northern District of West Virginia has upheld the validity of all of its patents related to Perforomist formoterol fumarate inhalation solution. The company says that… Read more . . .
-
Israeli pharmaceutical company Kamada has initiated a US Phase 2 trial of its inhaled alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency, also known as inherited emphysema. The company also announced a delay in… Read more . . .
-
Medical Developments UK (MDUK) has announced that it will donate 25p from the sale of each of its pMDI spacers in the UK to Asthma UK. MDUK is part of Medical Developments International, whose Space… Read more . . .
-
CDMO Formex, formerly PharmaForm, has hired Steve Massah as President and CEO. Massah joins Formex from Gilead, where he worked in Strategic Drug Product Manufacturing and Outsourcing. He has previously held management positions with Avanir,… Read more . . .
-
According to St. Renatus, Blue Ocean Holdings is investing an additional $5 million in the company. The funds will go toward completion of St. Renatus’s New Drug Application (NDA) for its nasal mist dental anesthesia… Read more . . .
-
GSK and Theravance have announced that results from three phase 3 studies comparing the Anoro Ellipta umeclidinium/vilanterol DPI to Advair and Seretide Diskus in COPD patients show greater improvement in lung function for patients treated… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK